{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:20:02Z","timestamp":1785280802506,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS119426"],"award-info":[{"award-number":["R01NS119426"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01133865"],"award-info":[{"award-number":["R01133865"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM144368"],"award-info":[{"award-number":["R01GM144368"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003138","name":"Mitochondrial Research Guild","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100003138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022186","name":"Lily Foundation","doi-asserted-by":"publisher","award":["Lily Foundation"],"award-info":[{"award-number":["Lily Foundation"]}],"id":[{"id":"10.13039\/501100022186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["Rosetrees Trust"],"award-info":[{"award-number":["Rosetrees Trust"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022098","name":"Mito Foundation","doi-asserted-by":"publisher","award":["Mito Foundation"],"award-info":[{"award-number":["Mito Foundation"]}],"id":[{"id":"10.13039\/501100022098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genetic mitochondrial diseases are a major challenge in modern medicine. These impact\u2009~\u20091:4,000 individuals and there are currently no effective therapies. Leigh syndrome is the most common pediatric presentation of mitochondrial disease. In humans, patients are often treated with antioxidants, vitamins, and strategies targeting energetics. The vitamin-E related compound vatiquinone (EPI-743, \u03b1-tocotrienol quinone) has been the subject of at least 19 clinical trials in the US since 2012, but the effects of vatiquinone on an animal model of mitochondrial disease have not yet been reported. Here, assessed the impact of vatiquinone in cellular assays and animal models of mitochondrial disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The efficacy of vatiquinone in vitro was assessed using human fibroblasts and HEK293 cells treated with the ferroptosis inducers RSL3 and BSO\u2009+\u2009Fe(III)Citrate, the mitochondrial oxidative stress inducer paraquat, and the electron transport chain complex I inhibitor rotenone. The therapeutic potential of vatiquinone in vivo was assessed using the tamoxifen-induced mouse model for GPX4 deficiency and the\n                      <jats:italic>Ndufs4<\/jats:italic>\n                      knockout mouse model of Leigh syndrome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Vatiquinone robustly prevented death in cultured cells induced by RSL3 or BSO\/iron, but had no effect on paraquat induced cell death. Vatiquinone had no impact on disease onset, progression, or survival in either the tamoxifen-inducible GPX4 deficient model or the\n                      <jats:italic>Ndufs4<\/jats:italic>\n                      (-\/-) mouse model, though the drug may have reduced seizure risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Vatiquinone prevents ferroptosis, but fails to attenuate cell death induced by paraquat or rotenone and provided no significant benefit to survival in two mouse models of disease. Vatiquinone may prevent seizures in the\n                      <jats:italic>Ndufs4<\/jats:italic>\n                      (-\/-) model. Our findings are consistent with recent press statements regarding clinical trial results and have implications for drug trial design and reporting in patients with rare diseases.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03582-x","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T14:15:36Z","timestamp":1739196936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the efficacy of vatiquinone in preclinical models of Leigh syndrome and GPX4 deficiency"],"prefix":"10.1186","volume":"20","author":[{"given":"Ernst-Bernhard","family":"Kayser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta A.","family":"Olkhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Coulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Hanaford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-3674","authenticated-orcid":false,"given":"Simon C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"3582_CR1","doi-asserted-by":"publisher","first-page":"600079","DOI":"10.3389\/fcell.2020.600079","volume":"8","author":"LD Schlieben","year":"2020","unstructured":"Schlieben LD, Prokisch H. The dimensions of primary mitochondrial disorders. Front Cell Dev Biol. 2020;8:600079.","journal-title":"Front Cell Dev Biol"},{"key":"3582_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1474-4422(22)00174-0","volume":"22","author":"NJ Newman","year":"2023","unstructured":"Newman NJ, Yu-Wai-Man P, Biousse V, Carelli V. Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management. Lancet Neurol. 2023;22:172\u201388.","journal-title":"Lancet Neurol"},{"key":"3582_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/B978-0-12-821751-1.00015-4","volume":"194","author":"S Rahman","year":"2023","unstructured":"Rahman S. Leigh syndrome. Handb Clin Neurol. 2023;194:43\u201363.","journal-title":"Handb Clin Neurol"},{"key":"3582_CR4","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1080\/15548627.2023.2218764","volume":"19","author":"Y Xie","year":"2023","unstructured":"Xie Y, Kang R, Klionsky DJ, Tang D. GPX4 in cell death, autophagy, and disease. Autophagy. 2023;19:2621\u201338.","journal-title":"Autophagy"},{"key":"3582_CR5","doi-asserted-by":"publisher","first-page":"232640981773301","DOI":"10.1177\/2326409817733013","volume":"5","author":"GM Enns","year":"2017","unstructured":"Enns GM, Cohen BH. Clinical trials in mitochondrial disease: an update on EPI-743 and RP103. J Inborn Errors Metabolism Screen. 2017;5:2326409817733013.","journal-title":"J Inborn Errors Metabolism Screen"},{"key":"3582_CR6","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.1073\/pnas.96.20.10948","volume":"96","author":"J Kaplan","year":"1999","unstructured":"Kaplan J. Friedreich\u2019s ataxia is a mitochondrial disorder. Proc Natl Acad Sci U S A. 1999;96:10948\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3582_CR7","doi-asserted-by":"publisher","first-page":"19655","DOI":"10.1074\/jbc.M601195200","volume":"281","author":"A Borchert","year":"2006","unstructured":"Borchert A, et al. The role of phospholipid hydroperoxide glutathione peroxidase isoforms in murine embryogenesis. J Biol Chem. 2006;281:19655\u201364.","journal-title":"J Biol Chem"},{"key":"3582_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2022.10.003","volume":"68","author":"D Amtmann","year":"2023","unstructured":"Amtmann D, Gammaitoni AR, Galer BS, Salem R, Jensen MP. The impact of TK2 deficiency syndrome and its treatment by nucleoside therapy on quality of life. Mitochondrion. 2023;68:1\u20139.","journal-title":"Mitochondrion"},{"key":"3582_CR9","doi-asserted-by":"publisher","first-page":"101879","DOI":"10.1016\/j.mito.2024.101879","volume":"76","author":"L Bermejo-Guerrero","year":"2024","unstructured":"Bermejo-Guerrero L, et al. Remarkable clinical improvement with oral nucleoside treatment in a patient with adult-onset TK2 deficiency: a case report. Mitochondrion. 2024;76:101879.","journal-title":"Mitochondrion"},{"key":"3582_CR10","unstructured":"Salviati L, Trevisson E, Agosto C, Doimo M, Navas P et al. in GeneReviews((R)), M. P. Adam Eds. (Seattle (WA), 1993)."},{"key":"3582_CR11","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.addr.2008.05.001","volume":"60","author":"MA Tarnopolsky","year":"2008","unstructured":"Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev. 2008;60:1561\u20137.","journal-title":"Adv Drug Deliv Rev"},{"key":"3582_CR12","doi-asserted-by":"publisher","first-page":"e0214250","DOI":"10.1371\/journal.pone.0214250","volume":"14","author":"AH Kahn-Kirby","year":"2019","unstructured":"Kahn-Kirby AH, et al. Targeting ferroptosis: a novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS ONE. 2019;14:e0214250.","journal-title":"PLoS ONE"},{"key":"3582_CR13","doi-asserted-by":"publisher","first-page":"19396","DOI":"10.1038\/s41598-022-23906-2","volume":"12","author":"KR Sekhar","year":"2022","unstructured":"Sekhar KR, et al. Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer. Sci Rep. 2022;12:19396.","journal-title":"Sci Rep"},{"key":"3582_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2017.07.010","volume":"112","author":"G Cozza","year":"2017","unstructured":"Cozza G, et al. Glutathione peroxidase 4-catalyzed reduction of lipid hydroperoxides in membranes: the polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center. Free Radic Biol Med. 2017;112:1\u201311.","journal-title":"Free Radic Biol Med"},{"key":"3582_CR15","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.4049\/jimmunol.1801232","volume":"203","author":"K Tsubouchi","year":"2019","unstructured":"Tsubouchi K, et al. Involvement of GPx4-Regulated lipid peroxidation in idiopathic pulmonary fibrosis pathogenesis. J Immunol. 2019;203:2076\u201387.","journal-title":"J Immunol"},{"key":"3582_CR16","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1126\/science.1244360","volume":"342","author":"SC Johnson","year":"2013","unstructured":"Johnson SC, et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013;342:1524\u20138.","journal-title":"Science"},{"key":"3582_CR17","doi-asserted-by":"publisher","first-page":"105594","DOI":"10.1016\/j.nbd.2021.105594","volume":"163","author":"R Bornstein","year":"2022","unstructured":"Bornstein R, et al. Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy. Neurobiol Dis. 2022;163:105594.","journal-title":"Neurobiol Dis"},{"key":"3582_CR18","doi-asserted-by":"crossref","unstructured":"Hanaford AR et al. Peripheral macrophages drive CNS disease in the Ndufs4(-\/-) model of Leigh syndrome. Brain Pathol, e13192 (2023).","DOI":"10.1111\/bpa.13192"},{"key":"3582_CR19","doi-asserted-by":"crossref","unstructured":"Stokes JC et al. Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome. JCI Insight 7, (2022).","DOI":"10.1172\/jci.insight.156522"},{"key":"3582_CR20","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.freeradbiomed.2012.02.043","volume":"52","author":"SE Yoo","year":"2012","unstructured":"Yoo SE, et al. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic Biol Med. 2012;52:1820\u20137.","journal-title":"Free Radic Biol Med"},{"key":"3582_CR21","doi-asserted-by":"crossref","unstructured":"Spencer KA et al. Volatile anaesthetic toxicity in the genetic mitochondrial disease Leigh syndrome. Br J Anaesth, (2023).","DOI":"10.1016\/j.bja.2023.08.009"},{"key":"3582_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14336\/AD.2020.0323","volume":"12","author":"J Ju","year":"2021","unstructured":"Ju J, Song YN, Wang K. Mechanism of ferroptosis: a potential target for Cardiovascular diseases Treatment. Aging Dis. 2021;12:261\u201376.","journal-title":"Aging Dis"},{"key":"3582_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ymgme.2011.10.009","volume":"105","author":"GM Enns","year":"2012","unstructured":"Enns GM, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab. 2012;105:91\u2013102.","journal-title":"Mol Genet Metab"},{"key":"3582_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40291-020-00510-6","volume":"25","author":"RJ Tinker","year":"2021","unstructured":"Tinker RJ, Lim AZ, Stefanetti RJ, McFarland R. Current and emerging clinical treatment in mitochondrial disease. Mol Diagn Ther. 2021;25:181\u2013206.","journal-title":"Mol Diagn Ther"},{"key":"3582_CR25","doi-asserted-by":"publisher","first-page":"14186","DOI":"10.1074\/jbc.M700827200","volume":"282","author":"PR Castello","year":"2007","unstructured":"Castello PR, Drechsel DA, Patel M. Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem. 2007;282:14186\u201393.","journal-title":"J Biol Chem"},{"key":"3582_CR26","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1074\/jbc.M708597200","volume":"283","author":"HM Cocheme","year":"2008","unstructured":"Cocheme HM, Murphy MP. Complex I is the major site of mitochondrial superoxide production by paraquat. J Biol Chem. 2008;283:1786\u201398.","journal-title":"J Biol Chem"},{"key":"3582_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4062\/biomolther.2015.075","volume":"23","author":"YJ Jang","year":"2015","unstructured":"Jang YJ, et al. Paraquat induces apoptosis through a Mitochondria-Dependent pathway in RAW264.7 cells. Biomol Ther (Seoul). 2015;23:407\u201313.","journal-title":"Biomol Ther (Seoul)"},{"key":"3582_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/15287390701738467","volume":"71","author":"W Yang","year":"2008","unstructured":"Yang W, Tiffany-Castiglioni E. Paraquat-induced apoptosis in human neuroblastoma SH-SY5Y cells: involvement of p53 and mitochondria. J Toxicol Environ Health A. 2008;71:289\u201399.","journal-title":"J Toxicol Environ Health A"},{"key":"3582_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/toxsci\/kfl125","volume":"95","author":"S Ramachandiran","year":"2007","unstructured":"Ramachandiran S, Hansen JM, Jones DP, Richardson JR, Miller GW. Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. Toxicol Sci. 2007;95:163\u201371.","journal-title":"Toxicol Sci"},{"key":"3582_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuint.2017.07.008","volume":"117","author":"J Byrnes","year":"2018","unstructured":"Byrnes J, et al. Pharmacologic modeling of primary mitochondrial respiratory chain dysfunction in zebrafish. Neurochem Int. 2018;117:23\u201334.","journal-title":"Neurochem Int"},{"key":"3582_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1021\/acs.chemrestox.0c00522","volume":"34","author":"J Innos","year":"2021","unstructured":"Innos J, Hickey MA. Using rotenone to Model Parkinson\u2019s Disease in mice: a review of the role of Pharmacokinetics. Chem Res Toxicol. 2021;34:1223\u201339.","journal-title":"Chem Res Toxicol"},{"key":"3582_CR32","doi-asserted-by":"publisher","first-page":"27425","DOI":"10.1074\/jbc.M115.667063","volume":"290","author":"JH Won","year":"2015","unstructured":"Won JH, Park S, Hong S, Son S, Yu JW. Rotenone-induced Impairment of Mitochondrial Electron Transport Chain Confers a selective Priming Signal for NLRP3 inflammasome activation. J Biol Chem. 2015;290:27425\u201337.","journal-title":"J Biol Chem"},{"key":"3582_CR33","doi-asserted-by":"publisher","first-page":"28097","DOI":"10.1074\/jbc.M115.680090","volume":"290","author":"L Chen","year":"2015","unstructured":"Chen L, Hambright WS, Na R, Ran Q. Ablation of the Ferroptosis Inhibitor Glutathione Peroxidase 4 in neurons results in Rapid Motor Neuron Degeneration and Paralysis. J Biol Chem. 2015;290:28097\u2013106.","journal-title":"J Biol Chem"},{"key":"3582_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymgme.2020.03.007","volume":"130","author":"SC Johnson","year":"2020","unstructured":"Johnson SC, et al. Regional metabolic signatures in the Ndufs4(KO) mouse brain implicate defective glutamate\/alpha-ketoglutarate metabolism in mitochondrial disease. Mol Genet Metab. 2020;130:118\u201332.","journal-title":"Mol Genet Metab"},{"key":"3582_CR35","doi-asserted-by":"crossref","unstructured":"Bolea I et al. Defined neuronal populations drive fatal phenotype in a mouse model of Leigh syndrome. Elife 8, (2019).","DOI":"10.7554\/eLife.47163"},{"key":"3582_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.braindev.2017.08.005","volume":"40","author":"T Kouga","year":"2018","unstructured":"Kouga T, et al. Japanese Leigh syndrome case treated with EPI-743. Brain Dev. 2018;40:145\u20139.","journal-title":"Brain Dev"},{"key":"3582_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ymgme.2012.09.007","volume":"107","author":"D Martinelli","year":"2012","unstructured":"Martinelli D, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease\u2013genetically defined Leigh Syndrome. Mol Genet Metab. 2012;107:383\u20138.","journal-title":"Mol Genet Metab"},{"key":"3582_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/00498254.2023.2245459","volume":"53","author":"J Ma","year":"2023","unstructured":"Ma J, et al. Absorption, distribution, metabolism and excretion of (14)C-vatiquinone in rats, dogs, and human subjects. Xenobiotica. 2023;53:396\u2013411.","journal-title":"Xenobiotica"},{"key":"3582_CR39","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/cpdd.1461","volume":"13","author":"L Lee","year":"2024","unstructured":"Lee L, et al. Effect of Itraconazole, a CYP3A4 inhibitor, and Rifampin, a CYP3A4 inducer, on the pharmacokinetics of Vatiquinone. Clin Pharmacol Drug Dev. 2024;13:1283\u201390.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3582_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13023-022-02495-3","volume":"17","author":"A Hanaford","year":"2022","unstructured":"Hanaford A, Johnson SC. The immune system as a driver of mitochondrial disease pathogenesis: a review of evidence. Orphanet J Rare Dis. 2022;17:335.","journal-title":"Orphanet J Rare Dis"},{"key":"3582_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.kint.2018.08.038","volume":"95","author":"SC Johnson","year":"2019","unstructured":"Johnson SC, et al. mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases. Kidney Int. 2019;95:455\u201366.","journal-title":"Kidney Int"},{"key":"3582_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fgene.2015.00247","volume":"6","author":"SC Johnson","year":"2015","unstructured":"Johnson SC, et al. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. 2015;6:247.","journal-title":"Front Genet"},{"key":"3582_CR43","doi-asserted-by":"publisher","first-page":"105594","DOI":"10.1016\/j.nbd.2021.105594","volume":"163","author":"R Bornstein","year":"2021","unstructured":"Bornstein R, et al. Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy. Neurobiol Dis. 2021;163:105594.","journal-title":"Neurobiol Dis"},{"key":"3582_CR44","doi-asserted-by":"publisher","first-page":"E4241","DOI":"10.1073\/pnas.1621511114","volume":"114","author":"M Ferrari","year":"2017","unstructured":"Ferrari M, et al. Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. Proc Natl Acad Sci U S A. 2017;114:E4241\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3582_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1126\/science.aad9642","volume":"352","author":"IH Jain","year":"2016","unstructured":"Jain IH, et al. Hypoxia as a therapy for mitochondrial disease. Science. 2016;352:54\u201361.","journal-title":"Science"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03582-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03582-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03582-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:26:51Z","timestamp":1739442411000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03582-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3582"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03582-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4202689\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed at Seattle Children\u2019s Research Institute (SCRI), followed SCRI guidelines, and were approved by the SCRI institutional animal care and use committee (IACUC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}